DATA GRAPHICS | Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
March 26, 2025 12:02 AM UTC
With Tuesday’s announcement that Hengrui is granting Merck & Co. ex-China rights to an oral small molecule lipoprotein(a) inhibitor, this year has brought at least eight deals where a Chinese company licensed products to a Western company in a therapeutic focus other than cancer.
Both Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276) and Merck & Co. Inc. (NYSE:MRK) have been among the more active players in cross-border partnerships, with the Chinese company also among the most active players out-licensing assets to “NewCos” backed by Western VCs...